Ask AI
ProCE Banner Activity

Treatment Decision Support for Evolving MCL Treatment Paradigms

Clinical Thought

Read this commentary to gain expert insight into the latest developments in mantle cell lymphoma (MCL) and learn about Decera Clinical Education’s treatment decision support tool, which provides expert recommendations for your patients with MCL.

Released: May 26, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma in the United States.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal treatments for patients with treatment-naive MCL, considering expert recommendations along with available efficacy and safety evidence

  • Identify patients with MCL most likely to benefit from chemotherapy-free treatment options

  • Plan therapeutic strategies for patients with relapsed/refractory MCL based on the clinical evidence and expert guidance on current and emerging treatment options

  • Evaluate emerging evidence for novel treatment options or combinations for patients with MCL

  • Manage toxicities associated with BTK inhibitor–based therapy to support adherence, appropriate dosing, and treatment continuation for optimal patient outcomes

Disclosure

Primary Author

Kami Maddocks, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, Autolous, Bristol Myers Squibb, Caribou, Genentech, Genmab, Incyte, Lilly.